{"url_path":"/sec/fulc/8-k/2026-04-27/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1680581/0001193125-26-178806-index.html","accession_number":"0001193125-26-178806","cik":"0001680581","ticker":"FULC","issuer_name":"Fulcrum Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1680581/0001193125-26-178806-index.html","primary_entity_key":"0001680581","primary_entity_name":"Fulcrum Therapeutics, Inc."},"word_count":177,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\nThe following exhibit is furnished herewith:\n\n \n\n10.1†\n\n[License Agreement, effective as of July 5, 2023, by and between CAMP4 Therapeutics Corp. and Fulcrum Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023).](https://www.sec.gov/Archives/edgar/data/1680581/000095017023059755/fulc-ex10_1.htm)\n\n99.1\n\n[Press Release issued April 27, 2026, announcing financial results for the quarter ended March 31, 2026](fulc-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n† Certain portions of this exhibit have been omitted because the registrant has determined that they are both not material and is the type of information that the registrant treats as private or confidential.\n\n+ Furnished herewith.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nFULCRUM THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nApril 27, 2026\n\nBy:\n\n/s/ Alex C. Sapir\n\n \n\n \n\n \n\nName: Alex C. Sapir\nTitle: President and Chief Executive Officer"}